NRX Pharmaceuticals Inc

NASDAQ:NRXP  
3.31
-0.30 (-8.31%)
Products, Regulatory

Nrx Pharmaceuticals Identifies Significantly Higher Likelihood Of Surviving And Recovering From Critical Covid-19 In Zyesami® (Aviptadil) Treated Patients Previously Administered Remdesivir

Published: 11/29/2021 12:41 GMT
NRX Pharmaceuticals Inc (NRXP) - Nrx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering From Critical Covid-19 in Zyesami® (aviptadil) Treated Patients Previously Administered Remdesivir.
Nrx Pharmaceuticals Inc - to Submit New Analysis and Safety Data to FDA in Support of Eua and Breakthrough Therapy Designation Requests.
Nrx Pharmaceuticals - Reanalysis of Clinical Trial Data Confirmed Statistically-significant 2-fold Survival Advantage in Patients Treated With Aviptadil Versus Placebo.
Nrx Pharma - Analysis Showed Statistically-significant 2.5 Fold Increased Odds of Being Alive, Free of Respiratory Failure at 60 Days in Patients Treated With Aviptadil Versus Placebo.
Nrx Pharma - Analysis Showed Statistically-significant 4-fold Higher Odds of Being Alive at Day 60 in Patients Treated With Aviptadil Versus Placebo.